Published in Women's Health Weekly, February 19th, 2000
Results were presented at the 7th Conference on Retroviruses and Opportunistic Infections, held January 30 - February 2, 2000, in San Francisco, California.
In this open-label study, HIV infected pregnant women ranging from 14 to 34 weeks of gestation were enrolled and received oral doses of 750 mg Viracept (nelfinavir mesylate)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly